Financial News

Financial Report: Amgen

Revenues up 2% despite competition for key products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen 3Q Revenues: $5.8 billion (+2%) 3Q Earnings: $2.0 billion (+8%) YTD Revenues: $17.0 billion (+6%) YTD Earnings: $5.8 billion (+13%) Comments: Enbrel sales were flat at $1.5 billion impacted by competition and unfavorable changes in inventory levels. Neulasta sales decreased 5% to $1.2 billion due to lower unit demand. Aranesp sales were up 8% to $531 million driven by a shift by some U.S. dialysis customers from EPOGEN to Aranesp. Sensipar/Mimpara sales increased 18% to $415...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters